lifestyle.digitaladblog.com

Author: ELI LILLY AND COMPANY

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

April 30, 2026
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

April 27, 2026
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

April 20, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

April 17, 2026
Lilly confirms date and conference call for first-quarter 2026 financial results announcement

April 16, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

April 16, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

April 13, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.

April 9, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.

April 9, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

April 1, 2026